SCHANGHAI, 13. September 2023 /PRNewswire/ — BioRay Pharmaceutical Co., Ltd. (im Folgenden bezeichnet als „Bioray”) gab vor Kurzem bekannt, dass sein eigenständig entwickeltes innovatives therapeutisches biologisches Präparat der Klasse I, Zuberitamab Injection (Handelsname: Anruixi®),…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.